Key facts
- This page summarizes Gregory T. Mayes's Form 4 filing for AVEO PHARMACEUTICALS, INC..
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 19 Jan 2023, 16:12.
Gregory T. Mayes - 19 Jan 2023 Form 4 Insider Report for AVEO PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 19 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Jan 2023, 16:12:52 UTC
- Prior SEC filing
- 08 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Danielle V. Holland, attorney in fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory T. Mayes filed Form 4 for AVEO PHARMACEUTICALS, INC. on 19 Jan 2023.
Change
- Previous filing in this sequence was filed on 08 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVEO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $6.10
- Footnotes
- F1
AVEO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -4,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- $7.52
- Footnotes
- F1
AVEO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $7.27
- Footnotes
- F1
AVEO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -22,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,500
- Exercise price
- $4.27
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Gregory T. Mayes is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
SEC remarks
On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").